![]() |
|
|
Vol. 295, Issue 1, 314-320, October 2000
The Parkinson's Institute, Sunnyvale, California
Excess activation of muscle nicotinic acetylcholine receptors due to
genetic mutations, as seen in slow channel congenital myasthenic
syndrome, or acetylcholinesterase (AChE) inhibition results in muscle
cell degeneration. Our recent work showed that nitric oxide synthase
(NOS) inhibitors prevent nicotine-induced muscle cell death in culture.
In the present study, we examined the effects of NOS inhibition on
nicotinic receptor-mediated myopathy in vivo. Rats injected with the
AChE inhibitor paraoxon demonstrate a 90-fold increase in the number of
dying muscle cells compared with control as evidenced histologically by
centralized nuclei and the presence of degenerating profiles.
Coadministration of the nonspecific NOS inhibitor
nitro-L-arginine methyl ester or the neuronal
NOS-specific inhibitor 7-nitroindazole dramatically reduced the
presence of such degenerating profiles to ~20% of that seen with
paraoxon alone. These results show that inhibition of NOS, as well as
neuronal NOS, significantly reduces AChE inhibitor-induced muscle cell
degeneration, suggesting that increased nitric oxide production
mediates such myopathy.